Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial

Graham R. Foster, Kosh Agarwal, Matthew E. Cramp, Sulleman Moreea, Stephen Barclay, Jane Collier, Ashley S. Brown, Stephen D. Ryder, Andrew Ustianowski, Daniel M. Forton, Ray Fox, Fiona Gordon, William M. Rosenberg, David J. Mutimer, Jiejun Du, Christopher L. Gilbert, Ernest Asante‐Appiah, Janice Wahl, Michael N. Robertson, Eliav Barr, Barbara Haber – 23 February 2018 – Many direct‐acting antiviral regimens have reduced activity in people with hepatitis C virus (HCV) genotype (GT) 3 infection and cirrhosis.

New scoring classification for primary biliary cholangitis–autoimmune hepatitis overlap syndrome

Wei Zhang, Debapriya De, Kahee A. Mohammed, Satish Munigala, Guilan Chen, Jin‐Ping Lai, Bruce R. Bacon – 20 February 2018 – Autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) are two major immune‐mediated chronic liver diseases. Overlap syndrome (OS) is diagnosed if patients have features of both AIH and PBC; however, there is no consensus on the definition or diagnostic criteria for OS. Here, we report a new scoring classification for OS and evaluate its usefulness.

Long‐term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy

Daniel Zamora‐Valdes, Kymberly D. Watt, Todd A. Kellogg, John J. Poterucha, Sara R. Di Cecco, Nicki M. Francisco‐Ziller, Timucin Taner, Charles B. Rosen, Julie K. Heimbach – 19 February 2018 – Obesity is increasingly common before and after liver transplantation (LT), yet optimal management remains unclear. The aim of this study was to analyze the long‐term outcomes for obese patients undergoing LT, including a noninvasive weight loss program and combined LT and sleeve gastrectomy (SG). Since 2006, all patients referred for LT with a body mass index (BMI) ≥35 kg/m2 were enrolled.

Subscribe to